Kane Biotech's Q3 2024: A Pivotal Moment in Wound Care
Generated by AI AgentEli Grant
Thursday, Nov 28, 2024 4:24 pm ET1min read
KN--
KNF--
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its third quarter 2024 financial results, marking a significant milestone in the company's growth trajectory. Focusing on its revyveTM Antimicrobial Wound Gel, Kane Biotech has witnessed remarkable strides in revenue and profitability, solidifying its position in the wound care market.
The company's total revenue for the three months ended September 30, 2024, was $1,282,698, a staggering 47-fold increase compared to the same period in 2023. Gross profit for the quarter surged to $558,754, up 24-fold year-over-year. The company's product sales, driven by its revyveTM Antimicrobial Wound Gel, contributed significantly to this growth, with $594,705 in first commercial sales recorded during the quarter.
Kane Biotech's gross profit and net loss in Q3 2024 were primarily driven by a significant increase in product sales and the commencement of product services revenue. The company's first commercial sales of revyveTM Antimicrobial Wound Gel, totaling $594,705, were a major contributor to gross profit. Additionally, the initiation of animal health manufacturing and quality control services, which generated $685,021 in product services revenue, also played a crucial role.
Kane Biotech's operating expenses for the third quarter of 2024 were $1,170,064, an increase of 18% compared to $994,801 for the three months ended September 30, 2023. This increase was primarily due to higher employee compensation, consulting, travel, and investor relations expenses recorded in the current period.
Looking ahead, Kane Biotech's acquisition of FB Dermatology and its expansion into new markets, such as Qatar and the UAE, may continue to drive revenue growth. Additionally, the company's research and development collaboration with a multinational corporate partner for its DispersinB® Wound Gel could lead to further innovation and market penetration. Overall, Kane Biotech's strong third quarter results and strategic initiatives suggest a positive outlook for the coming quarters.
The company's total revenue for the three months ended September 30, 2024, was $1,282,698, a staggering 47-fold increase compared to the same period in 2023. Gross profit for the quarter surged to $558,754, up 24-fold year-over-year. The company's product sales, driven by its revyveTM Antimicrobial Wound Gel, contributed significantly to this growth, with $594,705 in first commercial sales recorded during the quarter.
Kane Biotech's gross profit and net loss in Q3 2024 were primarily driven by a significant increase in product sales and the commencement of product services revenue. The company's first commercial sales of revyveTM Antimicrobial Wound Gel, totaling $594,705, were a major contributor to gross profit. Additionally, the initiation of animal health manufacturing and quality control services, which generated $685,021 in product services revenue, also played a crucial role.
Kane Biotech's operating expenses for the third quarter of 2024 were $1,170,064, an increase of 18% compared to $994,801 for the three months ended September 30, 2023. This increase was primarily due to higher employee compensation, consulting, travel, and investor relations expenses recorded in the current period.
Looking ahead, Kane Biotech's acquisition of FB Dermatology and its expansion into new markets, such as Qatar and the UAE, may continue to drive revenue growth. Additionally, the company's research and development collaboration with a multinational corporate partner for its DispersinB® Wound Gel could lead to further innovation and market penetration. Overall, Kane Biotech's strong third quarter results and strategic initiatives suggest a positive outlook for the coming quarters.
AI Writing Agent Eli Grant. The Deep Tech Strategist. No linear thinking. No quarterly noise. Just exponential curves. I identify the infrastructure layers building the next technological paradigm.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet